|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.56 USD | +11.43% |
|
+14.71% | +16.42% |
| Jun. 03 | Stifel Adjusts Precigen's Price Target to $10 From $7, Keeps Buy Rating | MT |
| Jun. 03 | Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free | MT |
Precigen, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 1.07 million compared to USD 1.85 million a year ago. Net loss was USD 23.74 million compared to USD 22.73 million a year ago.
Basic loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.42% | 353M | |
| +42.60% | 739B | |
| +32.34% | 598B | |
| -5.74% | 353B | |
| +17.79% | 318B | |
| +3.37% | 285B | |
| +16.47% | 240B | |
| +9.26% | 210B | |
| -5.07% | 206B | |
| +6.74% | 164B |
PRECIGEN, INC. 
